Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

This was a phase Ib, multi center, open-label, platform study with multiple treatment arms. The design of this study was adaptive to allow discontinuation of poorly tolerated or ineffective treatments and to facilitate the introduction of new candidate single agents or combinations. Study design included a dose escalation/confirmation part and a dose expansion. The planned initial single agent and combination treatment arms were the following: * Arm 1: MBG453 single agent * Arm 2: NIS793 single agent * Arm 3: canakinumab single agent * Arm 4: MBG453 + NIS793 combination * Arm 5: MBG453 + canakinumab combination Patients were treated in the dose confirmation/escalation part of the study in Arms 1, 2, 3 and 5. No patients were treated in Arm 4. The study did not progress into the expansion phase.